Navigation Links
ACORN CRO Continues Growth in Strong Third Quarter

Oncology Focused Contract Research Organization Exceeds Expectations

MEMPHIS, Tenn., Nov. 10 /PRNewswire/ -- ACORN CRO, a Contract Research Organization exclusively focused on oncology, announced today that its third quarter had once again exceeded projections as the company continues to experience banner growth. "The industry has responded favorably to ACORN's ability to consistently exceed client expectations, and we are ahead of projections in both number of projects, patients accrued, and revenue generated. Our strong, active relationship with community oncology and its physicians along with our proprietary technology provide sponsors with a combination for success," remarked Steve Coplon, ACORN CEO.

(Logo: )

ACORN CRO currently provides services for both specific cancer types and supportive care studies with additional projects ready to launch in the near future. Positioned for continued growth in 2009, ACORN CRO has expanded its staff and capabilities. ACORN CRO's experienced team provides sponsors with Project and Site Management; Data Management via Guardian EDC(TM); Statistics and Statistical Programming; and Medical and Scientific Writing.

Founded in community oncology and grounded with the most stringent scientific disciplines, ACORN CRO seamlessly incorporates the best of both worlds. "Though ACORN operates with a strong business model focused on operational success, scientific excellence guides our organization," according to Dr. Lee Schwartzberg, President and Chief Medical Director. Nationally recognized for his commitment to research at the community level, Dr. Schwartzberg co-founded Accelerated Community Oncology Research Network (ACORN), enabling oncologists nationwide to provide their patients the most promising research initiatives.

ACORN CRO evolved in response to sponsor requests for value-driven quality solutions and accelerated patient accruals. With a team approach, ACORN CRO lends itself to highly efficient and accurate trial operations. Close working relationships with community oncology practices enable prompt accruals.

"The trajectory of ACORN CRO for 2009 portends the most successful year for our company," stated Coplon. "We look forward to seeing sponsors at various meetings to showcase our abilities."

For additional information visit or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.


ACORN CRO is a full-service, oncology-focused contract research organization, providing value-driven, quality solutions to the pharmaceutical and biotech industry and offering unparalleled customer service in monitoring; clinical data management; statistical analysis; medical writing and project management. ACORN CRO delivers insights from key oncology opinion leaders and accelerates the research process through advanced levels of efficiency.

Contact Information:

Liz Conway

(901) 435-5570

Deborah D. Coble

901-683-0055 x1312

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
2. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
3. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
4. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
5. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
9. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... join physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for ... held in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
Breaking Biology News(10 mins):